Monitoring low molecular weight heparins at therapeutic levels: Dose-responses of, and correlations and differences between aptt, anti-factor xa and thrombin generation assays

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Thomas, Owain ^a   Lybeck, Emanuel ^a   Strandberg, Karin ^a,b   Tynngåd, Nahreen ^c   Schött, Ulf ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; THROMBIN; TINZAPARIN; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CORRELATIONAL STUDY; DOSE RESPONSE; DRUG MONITORING; EX VIVO STUDY; FLOW MEASUREMENT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; METABOLISM; MIDDLE AGED; PROTEIN DEGRADATION; YOUNG ADULT;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA INHIBITORS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTEOLYSIS; THROMBIN; YOUNG ADULT;

EID: 84921969922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116835     Document Type: Article

References (22)

1. Gouin-Thibault I, Pautas E, Siguret V (2005) Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 28: 333-349. PMID: 15783242
2. Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI (2002) In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 107: 241-244. PMID: 12479885
3. Kitchen S, Jennings I, Woods TA, Preston FE (1996) Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 49: 10-14. PMID: 8666677
4. Ip BK, Thomson AR, Moriarty HT (2001) A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology 33: 347-352. PMID: 11523938
5. Harris LF, Castro-Lopez V, Hammadi N, O'Donnell JS, Killard AJ (2010) Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. Talanta 81: 1725-1730. doi: 10.1016/j.talanta.2010.03.030 PMID: 20441964
6. Sibbing D, Spannagl M (2014) Direct oral anticoagulants and antiplatelet agents. Clinical relevance and options for laboratory testing. Hamostaseologie 34: 78-84. doi: 10.5482/HAMO-13-11-0055 PMID: 24301324
7. Greaves M (2002) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 87: 163-164. PMID: 11848446
8. Benchekroun S, Eychenne B, Mericq O, Colombani A, Douste-Blazy P, et al. (1986) Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis. Eur J Clin Invest 16: 536-539. PMID: 3104055
9. Al Dieri R, Alban S, Beguin S, Hemker HC (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4: 83-89. PMID: 16409456
10. Andrassy K, Eschenfelder V (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 81: S29-38. PMID: 8822125
11. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I (2007) Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5: 955-962. PMID: 17461929
12. Alban S, Welzel D, Hemker HC (2002) Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH. Semin Thromb Hemost 28: 369-378. PMID: 12244484
13. al Dieri R, Alban S, Beguin S, Hemker HC (2004) Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2: 1395-1401. PMID: 15304046
14. Gionis MN, Ioannou CV, Katsamouris AN, Katonis P, Balalis K, et al. (2013) The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. Thromb Res 132: 685-691. doi: 10.1016/j.thromres. 2013.09.037 PMID: 24182549
15. Meysman M, Haentjens P (2005) Pulmonary embolism: current treatment options. Curr Treat Options Cardiovasc Med 7: 483-490. PMID: 16283976
16. Sanfelippo MJ, Tillema VB (2009) Automated assay for fondaparinux (Arixtra) on the Dade Behring BCS XP. Am J Clin Pathol 132: 608-612. doi: 10.1309/AJCPA8KNNLLCV4JI PMID: 19762539
17. Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, et al. (2013) Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 139: 450-456. doi: 10.1309/AJCPS6OW6DYNOGNH PMID: 23525615
18. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, et al. (2002) Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87: 817-823. PMID: 12038783
19. Vermylen CG, Levin M, Lanham JG, Hardisty RM, Barratt TM (1987) Decreased sensitivity to heparin in vitro in steroid-responsive nephrotic syndrome. Kidney Int 31: 1396-1401. PMID: 3613410
20. White RH, Ginsberg JS (2003) Low-molecular-weight heparins: are they all the same? Br J Haematol 121: 12-20. PMID: 12670327
21. Kamal AH, Tefferi A, Pruthi RK (2007) How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82: 864-873. PMID: 17605969
22. Shi XB, Bai Y, Li J, Xiao J, Wang JQ, et al. (2013) Effects of low molecular weight heparin on clot rate and activated clotting time: an in vitro study. Chin Med J (Engl) 126: 3553-3556. PMID: 24034107.